Neumora Therapeutics, Inc. (NMRA)
- Previous Close
0.6629 - Open
0.6910 - Bid 0.5322 x 200
- Ask 0.8807 x 200
- Day's Range
0.6713 - 0.7697 - 52 Week Range
0.6210 - 17.1870 - Volume
1,198,957 - Avg. Volume
1,164,033 - Market Cap (intraday)
112.01M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5300 - Earnings Date Aug 4, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.29
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
www.neumoratx.comRecent News: NMRA
View More
Performance Overview: NMRA
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NMRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NMRA
View MoreValuation Measures
Market Cap
112.01M
Enterprise Value
-193.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-258.06M
Diluted EPS (ttm)
-1.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
0.65%
Levered Free Cash Flow (ttm)
--